USCB acquires ReMed Recovery Care Centers

US Community Behavioral, LLC ("USCB"), a leading multi-state provider of community-based residential and behavioral services, announced it has acquired ReMed Recovery Care Centers, LLC, a highly regarded provider of brain injury rehabilitation services based in Pennsylvania. The acquisition was made in partnership with ReMed's management team and will provide ReMed with support infrastructure and capital to expand its operations. ReMed will become a division of US Community Behavioral.

Martin Favis, the CEO of US Community Behavioral, noted, "ReMed is a leader and best-in-class provider of brain injury rehabilitation services. We are pleased to partner with its highly experienced management team to support its strategic initiatives in growing its business and further enhancing the excellent quality of care its patients receive."

Joanne Finegan, the President of ReMed, stated, "This transaction represents an exciting next step for ReMed, as part of a leading platform of community-based behavioral health services across the United States. ReMed's partnership with US Community Behavioral will provide resources and capital to continue to enhance the breadth and depth of our referral and patient relationships. We look forward to the opportunities ahead, especially as ReMed enters its 30th year."

US Community Behavioral was acquired in August by private investment firm Bregal Partners as a platform in the community-based behavioral health sector.

Terms of the transaction were not disclosed.

Source:

US Behavioral Community Behavioral 

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Monoamine neurotransmitters emerge as architects of brain physiology